Caninized anti-NGF antibodies and methods thereof
View Patent ↗The present disclosure encompasses novel caninized anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotides of the invention for the treatment and/or prevention of NGF related disorders, particularly for the management of canine pain.
1. An isolated caninized antigen binding protein that specifically binds to canine Nerve Growth Factor (NGF) comprising a variable light chain comprising SEQ ID NO. 26 (CAN-SSME3M-VL) and a variable heavy chain comprising SEQ ID NO. 27 (CAN-SSM57-VH).
2. The antigen binding protein of claim 1 wherein said antigen binding protein is a monoclonal antibody.
3. A veterinary composition comprising a therapeutically effective amount of the caninized antigen binding protein of claim 1 , and a pharmaceutically acceptable carrier.